title: Neuroprotective effect of thymoquinone, the nigella sativa bioactive compound, in 6-hydroxydopamine-induced hemi-parkinsonian rat model.
abstract: Parkinson disease (PD) is the most common movement disorder with progressive degeneration of midbrain dopaminergic neurons for which current treatments afford symptomatic relief with no-prevention of disease progression. Due to the neuroprotective property of the Nigella sativa bioactive compound thymoquinone (TQ), this study was undertaken to evaluate whether TQ could improve behavioral and cellular abnormalities and markers of oxidative stress in an experimental model of early PD in rat. Unilateral intrastriatal 6-hydroxydopamine (6-OHDA)-lesioned rats were daily pretreated p.o. with TQ at doses of 5 and/or 10 mg/Kg three times at an interval of 24 h. After 1 week, apomorphine caused contralateral rotations, a reduction in the number of neurons on the left side of the substantia nigra pars compacta (SNC) was observed, malondialdehyde (MDA) and nitrite level in midbrain homogenate increased and activity of superoxide dismutase (SOD) reduced in the 6-OHDA lesion group. TQ pretreatment significantly improved turning behavior, prevented loss of SNC neurons, and lowered level of MDA. These results suggest that TQ could afford neuroprotection against 6-OHDA neurotoxicity that is partly due to the attenuation of lipid peroxidation and this may provide benefits, along with other therapies, in neurodegenerative disorders including PD.
authors.affiliation: Department of Pathology and Anatomy, School of Medicine, Shahed University, Tehran, Iran.
authors.forename: Reza
authors.initials: R
authors.lastname: Sedaghat
authors.affiliation: Neurophysiology Research Center, Shahed University, Tehran, Iran.
authors.forename: Mehrdad
authors.initials: M
authors.lastname: Roghani
authors.affiliation: Neurophysiology Research Center, Shahed University, Tehran, Iran.
authors.forename: Mohsen
authors.initials: M
authors.lastname: Khalili
keywords: 6-Hydroxydopamine; Oxidative stress; Parkinson’s disease; Thymoquinone
references.citation: Neuropsychopharmacology. 2007 Dec;32(12):2570-80
references.pmid: 17356569
references.citation: J Neuroimmune Pharmacol. 2007 Jun;2(2):140-53
references.pmid: 18040839
references.citation: Mol Cell Biochem. 2012 Oct;369(1-2):55-65
references.pmid: 22752387
references.citation: Phytother Res. 2009 May;23(5):696-700
references.pmid: 19089849
references.citation: Behav Brain Res. 2011 Oct 31;224(2):305-10
references.pmid: 21699923
references.citation: Neurologist. 2011 Nov;17(6 Suppl 1):S18-20
references.pmid: 22045320
references.citation: BMC Neurosci. 2012 Jan 19;13:11
references.pmid: 22260211
references.citation: Brain Res Bull. 2010 Jul 30;82(5-6):279-83
references.pmid: 20558255
references.citation: Am J Ther. 2006 Sep-Oct;13(5):445-57
references.pmid: 16988541
references.citation: J Mol Histol. 2011 Feb;42(1):39-46
references.pmid: 21120684
references.citation: Exp Biol Med (Maywood). 2009 Apr;234(4):442-53
references.pmid: 19234050
references.citation: J Mol Histol. 2012 Apr;43(2):151-9
references.pmid: 22270828
references.citation: Neurologist. 2011 Nov;17(6 Suppl 1):S21-9
references.pmid: 22045322
references.citation: Biol Psychiatry. 2007 Dec 15;62(12):1353-62
references.pmid: 17624318
references.citation: Brain Res. 1987 Nov 24;426(2):323-31
references.pmid: 2446711
references.citation: Pharmacol Biochem Behav. 2009 Jun;92(4):642-8
references.pmid: 19327378
references.citation: Int Immunopharmacol. 2006 Jul;6(7):1135-42
references.pmid: 16714217
references.citation: Cell Tissue Res. 2004 Oct;318(1):215-24
references.pmid: 15503155
references.citation: Anal Biochem. 1976 May 7;72:248-54
references.pmid: 942051
references.citation: Iran J Pharm Res. 2012 Fall;11(4):1175-81
references.pmid: 24250551
references.citation: Nat Clin Pract Neurol. 2008 Nov;4(11):600-9
references.pmid: 18978800
references.citation: Cell Mol Neurobiol. 2010 May;30(4):591-8
references.pmid: 20054635
references.citation: J Neurosci Methods. 1980 Dec;3(2):129-49
references.pmid: 6110810
references.citation: Neurosci Lett. 2010 Aug 23;480(3):206-10
references.pmid: 20600617
references.citation: J Neurol. 2000 Apr;247 Suppl 2:II82-94
references.pmid: 10991671
references.citation: Brain Res. 2010 Apr 30;1328:139-51
references.pmid: 20167206
references.citation: Mov Disord. 2011 May;26(6):1049-55
references.pmid: 21626550
references.citation: J Cell Biochem. 2011 Jan;112(1):107-17
references.pmid: 20872780
references.citation: Biosci Biotechnol Biochem. 2012;76(3):536-43
references.pmid: 22451397
references.citation: Neurotoxicology. 1997;18(3):689-708
references.pmid: 9339817